REGISTRATION

Category1 Registration Type Fee
Club Member CSCC Members $150.00 plus applicable taxes
  Non-Members $175.00 plus applicable taxes
Single Roundtable CSCC Members $25.00 plus applicable taxes
  Non-Members $30.00 plus applicable taxes

All CSCC Education Roundtables will be held on Thursdays and will be one (1) hour in length.
Eastern Pacific Mountain Central Atlantic Newfoundland
ON, QC BC AB, SK* MB, ON (West) NB, NS, PE, Lab NL
11:30-12:30 08:30-09:30 09:30-10:30 10:30-11:30 12:30-13:30 13:30-14:30
14:00-15:00 11:00-12:00 12:00-13:00 13:00-1400 15:00-16:00 16:00-17:00
* SK - During daylight savings time; otherwise one hour later

Register Today!

1Save today! Club members are entitled to join any or all of the Roundtables. Register once only once automatically receive an invitation for each Roundtable and access to the slides and recordings of past roundtables for the current year.

  • Registration is by pre-payment only using the online registration form.  
  • Each registration is restricted to one (1) phone line; you may have as many participants using that line as you wish.
  • Participants will be sent a 1-800 phone number for the audio and an internet url to view the slides.

CLICK BUTTONS BELOW TO EXPAND THE MENU AND GET ALL THE DETAILS!

» How to Obtain and Submit your Professional Development Program (PDP) Credits

During the Roundtable presentation a Continuing Education (CE) Code will be displayed.

Record this code, you will not be able to submit for CE credit without it. 

MEMBERS ENTERING YOUR CREDITS
  • Login to your profile
  • Locate the Membership Tools menu (left)
  • Select CE Code Entry 
  • Enter the CE Code for the program and click on the Add button
    • Repeat to add all sessions that you wish to report
  • Enter your Credit Hours for each session or sessions
  • Once complete click Update Hours
  • Click Finalize Session List
    • On the next page, you may be required to submit a survey for the program.
    • Once done, check the I confirm that I have properly completed all the necessary surveys box
    • Click the Next button to continue.
  • Click the Proceed to Certificate button to view/progress to the summary page
  • Click the Download Certificate button to generate your certificate
NON-MEMBERS
  • Go to the CSCC website www.cscc.ca 
  • On the Main Menu, hover over Events
  • Select Non-Member Certificates 

» How to View/Access Past Education Roundtables

Education Roundtables during the Current Year:

  • Only those who have paid for the current series may access the previous roundtables in that series. 
    • Log in to your profile
      • On the Main CSCC Menu, hover over Chemist Library
      • Select Archived Roundtables & Lectureships

Education Roundtables from Previous Years:

  • These are available to all members in good standing. And will be made available only after the frsit date of the next years' series is complete.
    • Log in to your profile
      • On the Main CSCC Menu, hover over Chemist Library
      • Select Archived Roundtables & Lectureships

#01 October 5 2017 │ Next Generation Sequencing - Benefits and Challenges

Topic: Next Generation Sequencing - benefits and challenges
Session Description: In recent years there is a significant increase in next generation based assays for clinical diagnostics. Molecular testing has rapidly been moving from mutation specific and single gene assays to multi-gene panels, often more than 500 genes (exome slice), to whole genome sequencing. The aim of this session is to explore their current clinical applications, and their impact on clinical assessment and molecular diagnostics as part of the precision medicine effort. The discussion will highlight clinical validity of NGS based assays developed and validated by clinical laboratories and provide participants with the knowledge necessary to integrate clinical genomic sequencing into their practices.
Learning Objectives:

At the end of this session, participants will be able to:

  1. Identify the newest technologies and methods used in Next Generation Sequencing (NGS) and whole genome sequencing
  2. Discuss current guidelines and practices for interpreting NGS results and return of results to physicians and patients
  3. Provide context on the benefits and challenges of using NGS in the diagnosis and treatment of patients
About the Speaker(s):

Lianna Kyriakopoulou, PhD, FCACB, DABMG, FACMG
Director, Genome Diagnostics
The Hospital for Sick Children, Toronto

Dr. Lianna Kyriakopoulou is currently the director of Genome Diagnostics at the Hospital for Sick Children. She received her PhD in Microbiology and Molecular and Medical Genetics from the University of Toronto. She is certified by the Canadian Academy of Clinical Biochemistry and the American College of Medical Genetics in Clinical Molecular Genetics. She has worked as a Clinical Biochemist in the Genetic Metabolic Diseases laboratory and special chemistry at the Hospital for Sick Children.

Dr. Kyriakopoulou’s research interests include development of genomic tests for the diagnosis and treatment of Inborn Errors of Metabolism and neuromuscular disorders and quality management for high-complexity clinical laboratory testing.

#02 October 19 2017 │ Canadian Protein Electrophoresis Reporting Standardization Initiative

Topic: The Long and Winding Road: The Canadian Protein Electrophoresis Reporting Standardization Initiative
Session Description: This presentation will describe experiences with the Monoclonal Gammopathy Working Group initiative on standardization of protein electrophoresis reporting in Canada. It will provide the history of the intiative, current status, and future directions. Examples of challenges and successes of the iniatitve will be described. A summary of the lessons learned along the journey will be provided.
Learning Objectives:

At the end of this session, participants will be able to:

  1. Describe the Monoclonal Gammopathy Working Group standardization initiative
  2. List challenges and solutions associated with group standardization projects
  3. Describe the long term strategy for protein electrophoresis standardization in Canada
About the Speaker(s):

Dr. Christopher McCudden, Dr. Ronald Booth

Dr. Christopher McCudden
Clinical Biochemist, Division of Biochemistry, The Ottawa Hospital
Associate Professor, Dept. of Pathology & Lab. Medicine, University of Ottawa
501 Smyth Rd. Ottawa ON, Canada, K1H 8L6
Tel: 613-737-8899 Ex. 74850
E-mail: cmccudden@toh.on.ca

 

Dr. Ronald A. Booth, FCACB, FACB
Clinical Biochemist, Division of Biochemistry, The Ottawa Hospital
Associate Professor, Department of Pathology & Laboratory Medicine, University of Ottawa
501 Smyth Rd.  Ottawa ON, Canada, K1H 8L6 
Email: rbooth@toh.ca 

 

#03 November 2 2017 │ Anti-nuclear Antibodies: Challenges for the Clinical Diagnostic Laboratory

Topic: Anti-nuclear antibodies: Challenges for the clinical diagnostic laboratory
Session Description: For over 50 years, screening for anti-nuclear antibodies (ANA) associated with systemic autoimmune rheumatic diseases has been performed by indirect immunofluorescence assays (IIF) using cellular substrates followed by the interpretation of the staining patterns. This method has been the favored as the “gold standard” method by the American College of Rheumatology and has been the focus for the Choosing Wisely campaigns in North America. However, reduced technical laboratory expertise, limited laboratory resources, the increasing incidence of autoimmune diseases worldwide, increasing requests by non-rheumatologists, and the consequent increase in diagnostic testing are posing challenges to the clinical laboratory. This presentation will discuss the clinical utility of ANA testing, as well as recent advances in technology such as multiplex immunoassays and IIF interpretive digital software to help laboratory professionals to make informed decisions regarding ANA method evaluations.
Learning Objectives:

At the end of this session, participants will be able to:

  1. Understand the basics of anti-nuclear antibody (ANA) testing in diagnosis and management of autoimmune diseases.
  2. Understand current methods of ANA testing.
  3. Appreciate the advantages and disadvantages of the different ANA testing techniques.
  4. Understand the utility of ANA testing in the healthcare system.
About the Speaker(s):

Alex C. Chin, Ph.D. DABCC FACB FCACB
Clinical Chemist and Clinical Assistant Professor
Calgary Laboratory Services and the Department of Pathology and Laboratory Medicine
Cumming School of Medicine, University of Calgary

Dr. Alex Chin is a Clinical Biochemist at Calgary Laboratory Services and Clinical Assistant Professor of Pathology and Laboratory Medicine at the University of Calgary Cumming School of Medicine. At Calgary Laboratory Services, Dr. Chin oversees the immunochemistry clinical laboratory which performs tests in the clinical immunology (autoimmunity, allergy, infectious disease serology) and endocrinology specialties.

He received his undergraduate (B.Sc.) and graduate degrees (M.Sc. and Ph.D.) in immunopathology of bacterial pneumonia and intestinal parasitic infections at the University of Calgary. He proceeded with his postdoctoral research training in leukocyte and epithelial pathobiology, and clinical laboratory specialty training in clinical chemistry at Emory University in Atlanta.

He is board-certified in Clinical Chemistry by the American Board of Clinical Chemistry and is a fellow of the American Association for Clinical Chemistry Academy of Clinical Biochemistry and the Canadian Academy of Clinical Biochemistry. He is also the current co-director of the clinical biochemistry postdoctoral fellowship program at Calgary Laboratory Services/Department of Pathology and Laboratory Medicine at the University of Calgary Cumming School of Medicine.

#04 November 16 2017 │ The Need for Clinical Pathology Consultation in Primary Care

Topic: The Need for Clinical Pathology Consultation in Primary Care
Session Description: Primary care physicians face many challenges in their daily practice, mainly due to the limited time they have with their patients. With regards to laboratory testing, there is limited time to research which lab tests are best for their patients. This leads to over and underutilization of lab testing, which often leads to a delay in diagnosis or misdiagnosis. Clinical pathologists have the potential to help primary care providers improve these two issues so that patients are diagnosed in a timely manner. This presentation will provide several examples in daily practice where input from a clinical pathologist would be valuable. In addition, Dr. Segal provides several examples of potential solutions to these challenges, some of which have been implemented already and others that are in progress.
Learning Objectives: At the end of this session, participants will be able to:
1) Understand the challenges in the diagnostic process in today's medical environment
2) Because of the challenges, there is over and underutilization of the clinical laboratory which can leade to misdiagnosis and/or delayed diagnosis
30 Laboratory tests involve complex biochemistry that if not interpreted in the right clinical context may lead the clinician down the wrong path - pun intended
4) Identify how a Clinical Pathologist can have a tremendous positive influence in improving the diagnositc process.
About the Speaker(s): Graham V. Segal MD, Assistant Professor, UT Houston McGovern Medical School

#05 November 30 2017 │ CHMS- Its Role in Monitoring Canadians’ Health from Coast to Coast

Topic: CHMS- its role in monitoring Canadians’ health from coast to coast
Session Description: The Canadian Health Measures Survey (CHMS) is a national survey that is led by Statistics Canada, in partnership with Health Canada and the Public Health Agency of Canada, which collects information from Canadians about their general health. The CHMS is the most comprehensive, direct health measures survey conducted in Canada and is designed to represent the Canadian population. Through personal interviews and the collection of physical measurements, the survey provides baseline data on indicators of environmental exposures, chronic diseases, infectious diseases, fitness, and nutritional status, as well as risk factors and protective characteristics related to these areas. The physical measurements include such factors as height and weight, blood pressure, physical fitness and lung function measures, as well as many clinical chemistry measures based on blood and urine samples.
Learning Objectives: At the end of this session, participants will be able to:
1) understand the mandate of the CHMS and its role in monitoring the health of Canadians.
2) Be familiar with which clinical chemistry measures the CHMS looks at, and some of the important research that is being done with CHMS data.
About the Speaker(s): Dr. Audra Nagasawa, Laboratory Content Manager, CHMS, Statistics Canada

#06 December 14 2017 │ 1130-1230 ET │ Identification and Measurement of Fentanyl and Related Analogues...

Topic: Identification and measurement of fentanyl and related analogues: experiences at the Alberta OCME
Session Description: The Alberta Office of the Chief Medical Examiner examines around 4000 sudden deaths each year, of which 2500+ undergo detailed toxicological investigation.  Due to the increase and nature of the opioid deaths that have occurred over the past 6 years, the strategy for routine screening and confirmation of drugs has changed significantly from an ELISA and GC-MS based screen to one that primarily uses LC-TOF and LC-MS/MS.  For example, in 2016 Alberta recorded over 350 illicit fentanyl and analogue related deaths. Therefore in order to reliably detect and measure potent drugs such as 3-methylfentanyl and carfentanil, and to be able to detect newer, potent opioid analogues that are not yet in circulation, our screening strategy had to change in terms of both scope and sensitivity.
Learning Objectives:

At the end of this session, participants will be able to:

  • Understand the approaches used for the detection and measurement of fentanyl and other potent opioids in blood
  • Understand the strategies used to learn which opioids are likely to be, or are, present in the community
About the Speaker(s):

Dr. Graham Jones, Ph.D.
Chief Toxicologist, Alberta Medical Examiners Office

Dr. Graham Jones is Chief Toxicologist for the Alberta Office of the Chief Medical Examiner. He qualified as a Pharmacist in the U.K. later earning his Ph.D. degree in Pharmaceutical Chemistry (Drug Metabolism) at the University of London.  Dr. Jones later joined the University of Alberta Hospital as a Clinical Toxicologist.  In 1981 he joined the Alberta Office of the Chief Medical Examiner as director of the new forensic toxicology laboratory.

Dr. Jones is a past-President of the American Academy of Forensic Sciences (AAFS), past-President of the Society of Forensic Toxicologists, past-President of the Forensic Specialties Accreditation Board, and Chair of the Laboratory Accreditation Program of the American Board of Forensic Toxicology.  Dr. Jones has served as a consultant and expert witness in several toxicology-related murder trials in both Canada and the USA.

#07 January 4 2018 | 1400-1500 ET | 45+ Years of Clinical Biochemistry

Topic: 45+ Years of Clinical Biochemistry
Session Description: In the presentation I will review the progession of clinical biochemistry in the past 45 years.  These progressions are see in the pre and post analytical phases, and in the ancillary processes associated with clinical biochemistry.  Changes in methodology and instrumentation will be discussed
Learning Objectives: At the end of this session, participants will be able to:
1) understand the recent history of Clinical Biochemistry
2) understand the challenges in developing clinical biochemistry to its current state
3) understand how current clinical biochemistry is influenced by the past
About the Speaker(s): Trefor Higgins, Section Head, Department of Clinical Biochemistry, University of Alberta Hospitals
  Trefor Higgins was born in the United Kingdom.  He studied at Univiersities in Canada and the United Kingdom.  He has published over 200 papers and abstracts and has written severla textbook chapters.  He is the recipient of numerous awards.  Currently he is on the IFCC Task Force on Ethics.  He currently serves as Interim Section Head of Clinical Biochemistry at the University of Alberta in Edmonton.

#08 January 18 2018 │ 1130-1230 ET │ Pain Management: Cases and Guidelines

Topic: Pain Management: Cases and Guidelines
Session Description: In light of the “Opioid Crisis” when these drugs are used for pain management, compliance
monitoring is viewed as necessary for safe prescribing. While urine drug testing is currently
regarded as the standard for adherence monitoring of patients taking controlled substances, urine
drug testing results are frequently ordered and interpreted by distinctly different sets of individuals,
who frequently do not have the necessary knowledge of which tests to order or how to interpret
the results. This is where the Clinical Laboratory can have maximal impact. The goal is to provide
evidence-based recommendations on which tests to provide and assist with interpretations to
support our clinical colleagues and patients.
Learning Objectives: At the end of this session, participants will be able to:
1) Recognize the clinical utility and limitations of urine drug tests used to support pain management and monitoring of controlled substance
2) Define metabolic profiles of common classes of pain management medications
3) Identify the laboratory practice guidelines for laboratory support of a pain management practice
About the Speaker(s): Dr. Loralie Langman, Professor of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine 
  Dr. Langman completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta, and Clinical
Chemistry Fellowship at the University of Toronto. She is certified with the CACB and is the first individual
certified with the ABCC in Clinical Chemistry, Molecular Diagnostics, and Toxicological Chemistry. She is also
a Fellow with the American Board of Forensic Toxicology.

She is the Director of the Clinical and Forensic Toxicology Laboratory, Clinical Mass Spectroscopy Laboratory,
Personaized Genomics Laboratory and Professor of Laboratory Medicine and Pathology, Mayo Clinic College
of Medicine, Rochester, MN

She has numerous publications, abstracts, and book chapters; most relevant to today’s talk Co-Chaired the
Laboratory Medicine Practice Guideline “Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain
Management Patients”

#09 February 1 2018 │ 1400-1500 ET │CSA Standard and Toolkit

Topic: CSA Standard and Toolkit: Z316.7-12 Requirements for collecting, transporting, and storing samples
Session Description: An overview of CSA Group's Z316.7 standard titled "Primary sample collection facilities and medical laboratories - Patient safety and quality of care".  Requirements for collecting, transporting, and storing samples will be presented.  the accompanying toolkit and its use will also be reviewed.  Finally, a new technical specification just published by ISO on the same topic will be introduced.
Learning Objectives: At the end of this session, participants will be able to:
1) Identify national and international standards that pertain to pre-examination processes
2) Use the CSA Toolkit to improve their own processes.
About the Speaker(s): Mrs. Anne-Marie Martel, M.T., Head of Scientific Affairs, OPTMQ 
  Mrs. Martel is a medical technologist with over 20 years of experience.  She is currently head of scientific affairs at the OPTMQ (Ordre professionnel des technologistes médicaux du Québec).  She has been a member of CSA Group's technical committee on Medical Laboratory Quality Systems since 2008 and was appointed as chair in October 2017.  She is the chair of the technical subcommittee on specimen procurement that produced the Z316.7 standard and Toolkit.  She is a member of WG1 at ISO TC212.  She has been involved in the revision of many CLSI standards pertaining to sample collection and has been appointed chair of the Expert panel on pre-examination processes.

#10 February 15 2018 │ 1130-1230 ET │ TBA

Topic: TBA
Session Description: Coming Soon!
Learning Objectives:

At the end of this session, participants will be able to:

About the Speaker(s):  

#11 March 1 2018 │ 1130-1230 ET │ MSMS Maldi TOF

Topic: MSMS Maldi TOF
Session Description: Coming Soon!
Learning Objectives:

At the end of this session, participants will be able to:

About the Speaker(s): Dr. Mari DeMarco 

#12 March 22 2018│ 1400-1500 ET │ Sepsis, Procalcitonin and Antimicrobial Stewardship

Topic: Sepsis, Procalcitonin and Antimicrobial Stewardship
Session Description: CSCC Lectureship on Critical Care Medicine sponsored by Roche
Learning Objectives:

At the end of this session, participants will be able to:

About the Speaker(s):  

#13 April 12 2018 │ 1130-1230 ET │ Using Sigma Metrics for QC Rules and Monitoring Change

Topic: Using Sigma Metrics for QC Rules and Monitoring Change
Session Description: Coming Soon!
Learning Objectives:

At the end of this session, participants will be able to:

About the Speaker(s): Dr. Cynthia Balion 

#14 April 26 2018 │ 1400-1500 ET │ Newborn and Prenatal Screening - the benefits of using epidemiological data

Topic: Newborn and Prenatal Screening - the benefits of using epidemiological data
Session Description: Coming Soon!
Learning Objectives:

At the end of this session, participants will be able to:

About the Speaker(s): Dr. Bob Currier 

#15 May 17 2018 │ 1130-1230 ET │ Laboratory Markers for Inflammatory Bowel Disease

Topic: Laboratory Markers for Inflammatory Bowel Disease
Session Description: Laboratory markers are assuming increasing importance in the diagnosis of inflammatory bowel disease and in the monitoring of therapy. Fecal Calprotectin, in particular has been shown to be a valuable tool for distinguishing between Inflammatory Bowel Disease and Irritable Bowel Syndrome. The place for Fecal Calprotectin in the diagnostic algorithm for gastrointestinal disease will be presented. Other promising markers will also be discussed in the context of their diagnostic, prognostic and monitoring roles.
Learning Objectives: At the end of this session, participants will be able to:
1) understand the role of biomarkers in the diagnosis, prognosis and monitoring of inflammatory bowel disease
2) understand the issues presented by the specimens used for inflammatory disease investigation
3) understand the shortcommings of current inflammatory disease biomarkers
4) select an appropriate biomarker for the investigation of Inflammatory Bowel Disease
About the Speaker(s): Kent C. Dooley, PhD FCACB, Clinical Chemist, Lifelabs 
  Kent Dooley obtained his Ph.D. in chemistry from UBC This was followed by a clinical chemistry fellowship at the University of Texas in Houston where he was subsequently appointed to the position Assistant Professor of Pathology at the University of Texas Medical School. In 1981 he moved to the IWK Children’s Hospital in Halifax, Nova Scotia. In 1990 he assumed the role of Director and Chief of Pathology and Laboratory Medicine at the IWK Grace Health Center. From 2001 – 2003 he served as President of the Canadian Society of Clinical Chemists. In 2007 he took a position at LifeLabs, in Victoria, BC and Clinical Associate Professor of Pathology at UBC.

#16 May 31 2018 │ 1130-1230 ET │ 3 Presentations by Fellows-in-Training

Topic: 3 Presentations by Fellows-in-Training
Session Description: 1) Analytical Evaluation of the ß-hCG Assay on the Radiometer AQT90 Flex Immunoassay Analyzer
  2) Refining the Role of Ferritin in the Diagnosis of Iron Deficiency
 

3) Implementation of an aldosterone:renin ratio for screening primary hyperaldosteronism

Speaker: Dr. Felix Leung

Primary hyperaldosteronism (PA) is one of the primary causes of secondary hypertension but potentially curable with a definitive diagnosis.  However, invasive and/or burdensome procedures are required to confirm a diagnosis of PA and are thus only recommended in cases with high clinical suspicion.  For these reasons, an aldosterone:renin ratio (ARR) is recommended as a first-line screening tool to identify patients who should undergo further evaluation for PA.  Currently, the Endocrine Society has no recommendations for a standard ARR cut-off due to the variability (and dependence) on the assays used.  Thus, an outline of implementing a platform-specific ARR will familiarize laboratorians with important issues to consider when establishing this screening test for any laboratory.

At the conclusion of this session, participants will be able to:
1) Outline the Endocrine Society recommendations with respect to using the aldosterone:renin ratio for screening primary hyperaldosteronism
2) Discuss the challenges associated with establishing and implementing an aldosterone:renin ratio.

About the Speaker(s): 1) Dr. Miranda Brun
2) Dr. Michelle Parker
 

Dr. Felix Leung, Clinical Chemistry Fellow, University of Toronto

Felix Leung completed his PhD in 2016 at the University of Toronto studying ovarian cancer biomarkers and the biology of endometriosis-associated ovarian cancers.  Felix continued into his clinical chemistry fellowship at the same institution, completing rotations at Mount Sinai Hospital, University Health Network and The Hospital for Sick Children.  He has broad interests including mass spectrometry, endocrinology and informatics, as well as engaging the greater medical community in laboratory medicine through participation in the CSCC Working Group on Reference Interval Harmonization.

   

#17 June 21 2018 │ 1130-1230 ET │ TBA

Topic: TBA
Session Description: Coming Soon!
Learning Objectives:

At the end of this session, participants will be able to:

About the Speaker(s):